These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22308852)

  • 21. Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency.
    Scalco RC; Melo SS; Pugliese-Pires PN; Funari MF; Nishi MY; Arnhold IJ; Mendonca BB; Jorge AA
    J Clin Endocrinol Metab; 2010 Jan; 95(1):328-32. PubMed ID: 19926713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment.
    Lem AJ; van der Kaay DC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Jan; 98(1):77-86. PubMed ID: 23125290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial.
    Lem AJ; van der Kaay DC; de Ridder MA; Bakker-van Waarde WM; van der Hulst FJ; Mulder JC; Noordam C; Odink RJ; Oostdijk W; Schroor EJ; Sulkers EJ; Westerlaken C; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4096-105. PubMed ID: 22904179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty.
    van Gool SA; Kamp GA; Visser-van Balen H; Mul D; Waelkens JJ; Jansen M; Verhoeven-Wind L; Delemarre-van de Waal HA; de Muinck Keizer-Schrama SM; Leusink G; Roos JC; Wit JM
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1402-8. PubMed ID: 17284626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia.
    Quintos JB; Vogiatzi MG; Harbison MD; New MI
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1511-7. PubMed ID: 11297576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can the TW3 bone age determination method provide additional criteria for growth hormone treatment in adopted girls with early puberty? A comparison of the Tanner-Whitehouse 3 method with the Greulich-Pyle and the Tanner-Whitehouse 2 methods.
    Proos LA; Lönnerholm T; Jonsson B; Tuvemo T
    Horm Res Paediatr; 2010; 73(1):35-40. PubMed ID: 20190538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The alteration of IGF-1 levels and relationship between IGF-1 levels and growth velocity during GnRH analogue therapy.
    Muratoglu Sahin N; Peltek Kendirci HN; Çetinkaya S; Savaş Erdeve Ş; Aycan Z
    J Pediatr Endocrinol Metab; 2020 Jan; 33(1):113-120. PubMed ID: 31809263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study.
    Saggese G; Federico G; Barsanti S; Fiore L
    J Clin Endocrinol Metab; 2001 May; 86(5):1900-4. PubMed ID: 11344181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between serum insulin-like growth factor-1, IGF binding protein-3 levels and body height before and after gonadotropin-releasing hormone agonist therapy.
    Song HS; Choi WB; Song JS; Hwang IT; Yang S
    Ann Pediatr Endocrinol Metab; 2014 Dec; 19(4):208-13. PubMed ID: 25654067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced levels of GH during GnRH analogue treatment in pubertal short girls born small for gestational age (SGA).
    van der Kaay DC; Rose SR; van Dijk M; Noordam C; van Rheenen E; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):914-9. PubMed ID: 19178519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height.
    Toumba M; Bacopoulou I; Savva SC; Skordis N
    Indian Pediatr; 2007 Jul; 44(7):497-502. PubMed ID: 17684302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone.
    Mul D; Oostdijk W; Waelkens JJ; Drop SL
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):185-90. PubMed ID: 16060912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty.
    Swaiss HH; Khawaja NM; Farahid OH; Batieha AM; Ajlouni KM
    Saudi Med J; 2017 Nov; 38(11):1101-1107. PubMed ID: 29114697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay.
    Gorbenko del Blanco D; de Graaff LC; Visser TJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2012 May; 76(5):706-12. PubMed ID: 22117696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset.
    Li S; Wang X; Zhao Y; Ji W; Mao J; Nie M; Wu X
    Endocrine; 2020 Sep; 69(3):615-624. PubMed ID: 32533506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone.
    Vottero A; Pedori S; Verna M; Pagano B; Cappa M; Loche S; Bernasconi S; Ghizzoni L
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1284-7. PubMed ID: 16449342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.